Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy

Cancer Journal

Volumn 15, Issue 3, 2009, Pages 216-224

  Van Der Speeten, Kurt ^a   Stuart, Oswald A ^b   Sugarbaker, Paul H ^b  

^a DEPARTMENT OF CARDIOLOGY   (Belgium)

^b WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

Cisplatin; Doxorubicin; Fluorouracil; HIPEC; Irinotecan; Melphalan; Mitomycin; Oxaliplatin; Peritoneal carcinomatosis; Pharmacodynamics; Pharmacokinetics; Taxanes

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GLUCOSE; HYPERTONIC SOLUTION; HYPOTONIC SOLUTION; IRINOTECAN; ISOTONIC SOLUTION; MELPHALAN; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; THIOTEPA;

ABDOMINAL PRESSURE; ADVANCED CANCER; ANASTOMOSIS DEHISCENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BASEMENT MEMBRANE; BLOOD TOXICITY; BODY SURFACE; BODY TEMPERATURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CELL DEATH; CELL MEMBRANE; CLINICAL TRIAL; COLORECTAL CANCER; CONNECTIVE TISSUE; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DNA ADDUCT; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DIFFUSION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERANCE; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL TOXICITY; GILBERT DISEASE; HEAT TOLERANCE; HUMAN; HYPERGLYCEMIA; HYPERTHERMIA; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE; MESOTHELIUM CELL; MOLECULAR WEIGHT; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM MESOTHELIOMA; PERITONEUM PSEUDOMYXOMA; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; THROMBOCYTOPENIA; TISSUE DISTRIBUTION; WOUND HEALING IMPAIRMENT; METABOLISM; PERITONEUM TUMOR;

ANTINEOPLASTIC AGENTS; HUMANS; PERITONEAL NEOPLASMS;

EID: 67651161975     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181a58d95     Document Type: Review

References (121)

1. Sheperd NA, Baxter KJ, Love SB. The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation. Gastroenterology. 1997;112:1096-1102.
2. Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol. 1999;43(Suppl):S15-S25.
3. Oosterling SJ, Van der Bij GJ, Van Egmond M, et al. Surgical trauma and peritoneal recurrence of colorectal carcinoma. Eur J Surg Oncol. 2005;31:29-37. (Pubitemid 40103922)
4. Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545-1550.
5. Brodsky JT, Cohen AM. Peritoneal seeding following potentially curative resection of colonic carcinoma: implications for adjuvant therapy. Dis Colon Rectum. 1991;34:723-727.
6. Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63:364-367. (Pubitemid 19035034)
7. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358-363. (Pubitemid 30051820)
8. Verwaal VJ, Van Ruth S, De Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737-3743. (Pubitemid 46606227)
9. Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trail: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426-2432.
10. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681-685.
11. Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin N Am. 2003; 12:703-727.
12. Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267-272. (Pubitemid 34704979)
13. Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40:256-260. (Pubitemid 10140145)
14. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284-3292. (Pubitemid 41103684)
15. Glehen O, Mithieux F, Osinsky D, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol. 2003;21:799-806. (Pubitemid 46606438)
16. Yan TD, Black D, Sugarbaker PH, et al. A systematic review and metaanalysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for respectable gastric cancer. Ann Surg Oncol. 2007;14:2702-2713. (Pubitemid 47460649)
17. Bijelic L, Jonson A, Sugarbaker PH. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol. 2007;18:1943-1950. (Pubitemid 350286229)
18. Yan TD, Welch L, Black D, et al. A systematic review of the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18:827-834. (Pubitemid 47054078)
19. Yan TD, Black D, Savady R, et al. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2007;14:484-492. (Pubitemid 46175292)
20. Yan TD, Black D, Savady R, et al. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006;24:4011-4019. (Pubitemid 46630752)
21. Elias D, Glehen O, Gilly F. Carcinose péritonéales d'origine digestive et primitive. Rapport du 110 éme congrès de l'AFC. Arnette: Wolters Kluwer France; 2008.
22. Baron MA. Structure of the intestinal peritoneum in man. Am J Anat. 1941;69:439-497.
23. Flessner MF, Henegar J, Bigler S, et al. Is the peritoneum a significant transport barrier in peritoneal dialysis? Perit Dial Int. 2003;23:542-549. (Pubitemid 37527297)
24. De Lima Vazquez V, Stuart OA, Mohamed F, et al. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother Pharmacol. 2003;52:108-112. (Pubitemid 37041342)
25. Stelin G, Rippe B. A phenomenological interpretation of the variation in dialysate volume with dwell time in CAPD. Kidney Int. 1990;38:465-472. (Pubitemid 20258749)
26. Bettendorf U. Lymph flow mechanism of the subperitoneal diaphragmatic lymphatics. Lymphology. 1978;11:111-116. (Pubitemid 9015924)
27. Bettendorf U. Electronmicroscopic studies on the peritoneal resorption of intraperitoneally injected latex particles via the diaphragmatic lymphatics. Lymphology. 1979;12:66-70.
28. Katz MH, Barone RM. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am. 2003;12:673-688. (Pubitemid 36920092)
29. Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1-11.
30. Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol. 1985;12(3 Suppl 4):1-6.
31. Flessner MF, Fenstermacher JD, Dedrick RL, et al. A distributed model of peritoneal-plasma transport: tissue concentration gradients. Am J Physiol. 1985;248:F425-F435. (Pubitemid 15142313)
32. Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol. 2005;288:433-442.
33. Flessner MF. Intraperitoneal drug therapy: physical and biological principles. Cancer Treat Res. 2007;134:131-152.
34. Rubin J, Clawson M, Planch A, et al. Measurements of peritoneal surface area in man and rat. Am J Med Sci. 1988;295:453-458. (Pubitemid 18140013)
35. Keshaviah P, Emerson PF, Vonesh EF, et al. Relationship between body size, fill volume and mass transfer area coefficient in peritoneal dialysis. J Am Soc Nephrol. 1994;4:1820-1826. (Pubitemid 24976986)
36. Elias DM, Sideris L. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am. 2003;12:755-769. (Pubitemid 36920097)
37. Sugarbaker PH, Stuart OA, Carmignani CP. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol. 2006;57:703-708.
38. Gardner SN. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and-non-specific drugs. Cancer Res. 2000;60:1417-1425.
39. Mohamed F, Sugarbaker PH. Carrier solutions for intraperitoneal chemotherapy. Surg Oncol Clin N Am. 2003;12:813-824.
40. Pestieau SR, Schnake KJ, Stuart OA, et al. Impact of carrier solutions on the pharmacokinetics of intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 2001;47:269-276. (Pubitemid 32640763)
41. Mohamed F, Marchettini P, Stuart OA, et al. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother Pharmacol. 2003;52:405-410. (Pubitemid 37363614)
42. Kondo A, Maeta M, Oka A, et al. Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice. Br J Cancer. 1996;73:1166-1170. (Pubitemid 26162328)
43. Tsujitani S, Oka A, Kondo A, et al. Administration in a hypotonic solution is preferable to dose escalation in intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in rats. Oncology. 1999;57:77-82. (Pubitemid 29308675)
44. Elias D, Otmany A, Bonnay M, et al. Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology. 2002;63:346-352. (Pubitemid 36151527)
45. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst. 1997;89:480-487.
46. Esquis P, Consolo D, Magnin G, et al. High intraabdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental carcinomatosis. Ann Surg. 2006;244:106-112. (Pubitemid 44297454)
47. Jacquet P, Stuart OA, Chang D, et al. Effect of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anticancer Drugs. 1996;7:596-603. (Pubitemid 26276352)
48. Gesson-Paute A, Ferron G, Thomas F, et al. Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative chemotherapy (HIPEC): an experimental study. Ann Surg Oncol. 2008;15:339-344.
49. Thomas F, Ferron G, Gesson-Paute A, et al. Increased tissue diffusion of oxaliplatin during laparoscopically assisted versus open heated intraoperative intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2008;15:3623-3624.
50. Garofalo A, Valle M, Garcia J, et al. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol. 2006;32:682-685. (Pubitemid 44064001)
51. Facchiano E, Scaringi S, Kianmanesh R, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol. 2007;34:154-158.
52. Patriti A, Cavazzoni E, Graziosi L, et al. Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy. Surg Laparosc Endosc Percutan Tech. 2008;18:426-428.
53. Tannock IF, Lee CM, Tunggal JK, et al. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res. 2002;8:878-884.
54. Los G, Mutsaers PH, Lenglet WJ, et al. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol. 1990;25:389-394. (Pubitemid 20069336)
55. Los G, Verdegaal EM, Mutsaers PH, et al. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991;28:159-165.
56. Smeenk RM, Verwaal VJ, Antonini N, et al. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2007;245:104-109. (Pubitemid 46035441)
57. Sugarbaker PH, Chang D, Koslowe P. Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy. Cancer Treat Res. 1996;81:89-104.
58. Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003;12:689-701.
59. Dahl O, Dalene R, Schem BC, et al. Status of clinical hyperthermia. Acta Oncol. 1999;38:863-873.
60. Sugarbaker PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia. 2007;23:431-442.
61. Lepock JR. How do cells respond to their thermal environment? Int J Hyperthermia. 2005;21:681-687. (Pubitemid 41807093)
62. Kampinga HH. Cell biological effects of hyperthermia alone or combined with radiation or drugs: a short introduction to newcomers in the field. Int J Hyperthermia. 2006;22:191-196.
63. Hahn GM, Braun J, Har-Kedar I. Thermochemotherapy: synergism between hyperthermia (42-43°) and adriamycin (or bleomycin) in mammalian cell inactivation. Proc Nat Acad Sci. 1975;72:937-940.
64. Kusumoto T, Holden SA, Teicher BA. Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo. Int J Hyperthermia. 1995;11:575-586.
65. Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and Mitomycin C. Cancer Res. 1980;40:1165-1168. (Pubitemid 10135826)
66. Urano M, Ling CC. Thermal enhancement of melphalan and oxaliplatin cytology in vitro. Int J Hyperthermia. 2002;18:307-315. (Pubitemid 34700198)
67. Mohamed F, Marchettini P, Stuart OA, et al. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol. 2003;10:463-468. (Pubitemid 40486946)
68. Jacquet P, Averbach AM, Stuart OA, et al. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism and tissue distribution in a rat model. Cancer Chemother Pharmacol. 1998;41:147-154. (Pubitemid 28096269)
69. Tritton TR. Cell surface actions of adriamycin. Pharmac Ther. 1991;49:293-309.
70. Lane P, Vichi P, Bain DL, et al. Temperature dependence studies of adriamycin uptake and cytotoxocity. Cancer Res. 1987;47:4038-4042. (Pubitemid 17108466)
71. Johansen PB. Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. Cancer Chemother Pharmacol. 1981;5:267-270.
72. Ozols RF, Grotzinger KR, Fisher RI, et al. Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer. Cancer Res. 1979;39:3202-3208. (Pubitemid 9231828)
73. Ozols RF, Locker GY, Doroshow JH, et al. Pharmacokinetics and tissue penetration in murine ovarian cancer. Cancer Res. 1979;39:3209-3214.
74. Ozols RF, Young RC, Speyer JL, et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res. 1982;42:4265-4269.
75. Van der Speeten K, Stuart OA, Mahteme H, et al. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer Chemother Pharmacol. 2008;63:799-805.
76. Van Ruth S, Verwaal VJ, Zoetmulder FA. Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am. 2003;12:771-780.
77. Jacquet P, Averbach A, Stephens AD, et al. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology. 1998;55:130-138. (Pubitemid 28052257)
78. Smeenk RM, Verwaal VJ, Zoetmulder FA. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei. A report of 103 procedures. Eur J Surg Oncol. 2006;32:186-190.
79. Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10:863-869. (Pubitemid 40486849)
80. Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol. 2006;13:635-644.
81. Cepeda V, Fuertes MA, Castilla J, et al. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem. 2007;7:3-18.
82. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43. (Pubitemid 43048949)
83. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in smallvolume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001-1007. (Pubitemid 32176274)
84. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950-1955. (Pubitemid 26428219)
85. Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia. 1999;15:79-107. (Pubitemid 29149801)
86. Los G, Mutsaers PH, Van der Vijgh WJ, et al. Direct diffusion of cisdiamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 1989;49:3380-3384. (Pubitemid 19162154)
87. Van der Vaart PJ, van der Vange N, Zoetmulder FA, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer. 1998;34:148-154.
88. Jerremalm E, Hedeland M, Wallin I, et al. Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res. 2004;21:891-894. (Pubitemid 39011316)
89. De Somer F, Ceelen W, Delanghe J, et al. Severe hyponatremia, hyperglycemia and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int. 2008;28:61-66. (Pubitemid 351566127)
90. Czejka M, Jäger W, Schüller J, et al. Pharmacokinetics of carboplatin after intraperitoneal administration. Arch Pharm (Weinheim). 1991;324:183-184.
91. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7:2182-2194. (Pubitemid 32751614)
92. Wasserman E, Myara A, Lokiec F, et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol. 1997;8:1049-1051. (Pubitemid 27475739)
93. Guichard S, Chatelut E, Lochon I, et al. Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice. Cancer Chemother Pharmacol. 1998;42:165-170. (Pubitemid 28267299)
94. Maruyama M, Toukairin Y, Baba H, et al. Experimental study on CPT-11 intraperitoneal chemotherapy. Metabolism of CPT-11 in malignant ascites. Gan To Kagaku Ryoho. 2000;27:1858-1860.
95. Maruyama M, Toukairin Y, Baba H, et al. Pharmacokinetic study of the intraperitoneal administration of CPT-11 for patients with peritoneal seedings of gastric and colonic cancers. Gan To Kagaku Ryoho. 2000;28:1505-1507.
96. Maruyama M, Nagahama T, Yuassa Y. Intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis. Anticancer Res. 1999;19:4187-4191.
97. Choi SH, Tsuchida Y, Yang HW. Oral versus intraperitoneal administration of irinotecan in the treatment of nude mice. Cancer Lett. 1998;124:15-21.
98. Hribaschek A, Kuhn R, Pross M, et al. Intraperitoneal versus intravenous CPT-11 given intra- and postoperatively for peritoneal carcinomatosis in a rat model. Surg Today. 2006;36:57-62. (Pubitemid 43015856)
99. Elias D, Matsuhisa T, Sideris L, et al. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol. 2004;15:1558-1565. (Pubitemid 39409748)
100. Alberts DS, Chen HS, Chang SY, et al. The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients. Recent Results Cancer Res. 1980;74:293-299.
101. Glehen O, Stuart OA, Mohamed F, et al. Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model. Cancer Chemother Pharmacol. 2004;54:79-84. (Pubitemid 38858369)
102. Sugarbaker PH, Stuart OA. Pharmacokinetic and phase II study of heated intraoperative intraperitoneal melphalan. Cancer Chemother Pharmacol. 2007;59:151-155.
103. Pestiau SR, Stuart OA, Chang D, et al. Pharmacokinetics of intraperitoneal gemcitabine in a rat model. Tumori. 1998;84:706-711. (Pubitemid 29086532)
104. Sabbatini P, Aghajanian C, Leitao M, et al. Intraperitoneal Cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II trial. Clin Cancer Res. 2004;10:2962-2967. (Pubitemid 38619671)
105. Morgan RJ Jr., Synold TW, Bixin X, et al. Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res. 2007;13:1232-1237.
106. Gamblin TC, Egorin MJ, Zuhowski EG, et al. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas. Cancer Chemother Pharmacol. 2008;62:647-653.
107. Ceelen WP, Pahlman L, Mahteme H. Pharmacodynamic aspects of intraperitoneal cytotoxic therapy. Cancer Treat Res. 2007;134:195-214.
108. Sugarbaker PH, Mora JT, Carmignani P, et al. Update on chemotherapuetic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist. 2005;10:112-122. (Pubitemid 40261950)
109. Mohamef F, Sugarbaker PH. Intraperitoneal taxanes. Surg Oncol Clin N Am. 2003;12:825-833.
110. Rietbroek RC, Katschinski DM, Reijers MHE, et al. Lack of thermal enhancement for taxanes in vitro. Int J Hyperthermia. 1997;13:525-533.
111. Schrump DS, Zhai SP, Nguyen DM, et al. Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques. J Thorac Cardiovasc Surg. 2002;123:686-694.
112. Cividalli A, Cruciani G, Livdi E, et al. Hyperthermia enhances the response of paclitaxel and radiation in a mouse adenocarcinoma. Int J Radiat Oncol Biol Phys. 1999;44:407-412. (Pubitemid 29205040)
113. Mohamed F, Stuart OA, Glehen O, et al. Docetaxel and hyperthermia: factors that modify thermal enhancement. J Surg Oncol. 2004;88:14-20. (Pubitemid 39313815)
114. Yonemura Y, Bandou E, Sawa T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32:661-665. (Pubitemid 44063995)
115. De Bree E, Rosing H, Beijnen JH, et al. Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. Anticancer Drugs. 2003;14:103-110. (Pubitemid 36269748)
116. De Bree E, Rosing H, Filis D, et al. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. Ann Surg Oncol. 2008;15:1183-1192.
117. Mathé G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or 1-OHP, a third generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cisplatinum and carboplatinum. Biomed Pharmacother. 1989;43:237-250. (Pubitemid 19153975)
118. de Gramont A, Tournigand C, Louvet C, et al. [Oxaliplatin, folonic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD]. Rev Med Interne. 1997;18:769-775.
119. Nygren P, Fridborg H, Csoka K, et al. Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer. 1994;56:715-720. (Pubitemid 24086775)
120. Larsson R, Kristensen J, Sandberg C, et al. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer. 1992;50:177-185.
121. Mahteme H, von Heideman A, Grundmark B, et al. Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis. Eur J Surg Oncol. 2008;34:547-552.